DelveInsight Business Research LLP

DelveInsight’s “Liver Cirrhosis – Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Liver Cirrhosis, historical and forecasted epidemiology, and the Liver Cirrhosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Liver Cirrhosis Overview

Liver Cirrhosis is a late-stage liver disease in which healthy liver tissue is replaced with scar tissue and the liver is permanently damaged. In the developed world, the most common causes of cirrhosis are hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH), while hepatitis B virus (HBV) and HCV are the most common causes in the developing world. Other causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver cirrhosis, and chronic right-sided heart failure. 

Liver Cirrhosis Epidemiology Insights

• The total diagnosed prevalent cases of liver cirrhosis in the 7MM was 3,381,114 cases in 2022 which is expected to rise, at a significant CAGR during the study period (2019–2032).

• The highest diagnosed prevalent cases of liver cirrhosis were accounted for by the US in 2022, with 2,056,495 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population.

• Among the European countries, Germany had the highest diagnosed prevalent population of liver cirrhosis with 222,417 cases, followed by Italy (185,319 cases) in 2022. On the other hand, Spain had the lowest diagnosed prevalent population among the 7MM.

Click here to learn more about the Liver Cirrhosis Market Landscape

The Report Covers the Liver Cirrhosis Epidemiology Segmented by

• Liver Cirrhosis diagnosed prevalent cases 

• Etiology-Specific diagnosed prevalent cases 

Liver Cirrhosis Market Outlook 

With no approved therapies for advanced hepatic cirrhosis, treatments are urgently needed to stabilize or reverse fibrotic disease progression. The US FDA has approved several drugs to treat Congenital heart block, Community Health Centres, and Primary Biliary Cholangitis, but none target cirrhosis patients. There is, however, growing optimism that new medications that favor the natural history of the disease are likely to emerge within the next 3–5 years.

Key Companies Working in the Liver Cirrhosis Market

Madrigal Pharmaceuticals, Inc.

Galectin Therapeutics Inc.

Grifols Therapeutics LLC

CymaBay Therapeutics

Akero Therapeutics, Inc.

NGM Biopharmaceuticals, Inc.

And many others 

Liver Cirrhosis Therapies Covered and Analyzed in the Report:

• Resmetirom (MGL-3196)

• Efruxifermin (AKR-001)

•  SB-1121

•  G-CSF

•  ZES

And many others.

Learn more about the Key Companies and Emerging Therapies in the Liver Cirrhosis Market

Table of Contents 

1.  Key Insights 

2.  Liver Cirrhosis  Introduction 

3.  Executive Summary of Liver Cirrhosis         

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Liver Cirrhosis  Emerging Therapies

7.  Liver Cirrhosis  Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Liver Cirrhosis Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services